Long‐term bosutinib for chronic phase chronic myeloid leukemia after failure of imatinib plus dasatinib and/or nilotinib

Bosutinib is an Src/Abl tyrosine kinase inhibitor (TKI) indicated for adults with Ph+ chronic myeloid leukemia (CML) resistant/intolerant to prior TKIs. This long‐term update of an ongoing phase 1/2 study evaluated the efficacy and safety of third‐/fourth‐line bosutinib in adults with chronic phase...

Descripción completa

Detalles Bibliográficos
Autores principales: Cortes, Jorge E., Khoury, Hanna J., Kantarjian, Hagop M., Lipton, Jeff H., Kim, Dong‐Wook, Schafhausen, Philippe, Matczak, Ewa, Leip, Eric, Noonan, Kay, Brümmendorf, Tim H., Gambacorti‐Passerini, Carlo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2016
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303616/
https://www.ncbi.nlm.nih.gov/pubmed/27531525
http://dx.doi.org/10.1002/ajh.24536

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303616/
https://www.ncbi.nlm.nih.gov/pubmed/27531525
http://dx.doi.org/10.1002/ajh.24536

Ejemplares similares